Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07109258

Effect of Dexamethasone on Labour Induction in Term Pregnancies

The aim of the study is to assess the effect of dexamethasone on labour induction in term pregnancies.

Primary outcome:

The interval between initiation of induction and beginning of the active phase of labour.

Secondary outcomes:

* Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation). * Duration of second stage of labour * Mode of delivery. * Fetal outcome.

Group A:

Will receive one dose of IM dexamethasone sodium phosphate 8 mg (2 mL).

Group B:

Will receive vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.

Group C:

Will receive one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

Cairo University Hospital (Kasr Al Ainy)

Cairo, Manial, 11562, Egypt

Location status: Recruiting

Location contact

Abdelfatah M Eldesouky, MD, MRCOG

CONTACT

[email protected]

00201003370784

About this study

  • Study type: Randomized Controlled Trial
  • Population of study:

Pregnant women above 18 years of age, eligible for induction of labour.

● Study location: Cairo University Obstetrics & Gynecology Hospital (Kasr Al-Ainy)

  • Methodology in details:
  • Every subject will be subjected to:
  • Written consent.
  • Complete history to exclude systemic disorders, congenital fetal malformation and contraindications for vaginal delivery.
  • General examination of the patients including pulse, blood pressure and body mass index, [weight (kg)/ height (m2)] (20-25) normal weight, (25-30) overweight, (30-35) obese, (35-40) very obese and >40 morbid obese.
  • Abdominal examination including presentation, station of fetal head, fetal heart rate, uterine contractions and exclusion of multiple pregnancies.
  • Local examination to determine cervical dilatation at the beginning of intervention, presenting part, station of fetal head, pelvic adequacy and Bishop scoring.
  • Sonographic examination including assessment of fetal well-being by biophysical profile.
  • Patients will be randomly assigned to three groups using simple randomization via computer-generated random numbers will be used.
  • The women will be divided into three groups:
  • Group A: They will receive one dose of IM dexamethasone sodium phosphate 8 mg (2 mL).
  • Group B: They will receive vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.
  • Group C: They will receive one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.
  • Regarding group A,B and C the investigators will wait 24hrs after the last dose, then reassessment by senior obstetrician will be done and if induction is unsuccessful it'll be determined whether the patient is for either CS or second 24hr attempt at induction by misoprostol.
  • Primary outcome:

The interval between initiation of induction and beginning of the active phase of labour.

  • Secondary outcomes:
  • Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation).
  • Duration of second stage of labour
  • Mode of delivery.
  • Fetal outcome.
  • Sample size Assuming that the mean interval between the start of induction and the beginning of the active phase among cases 2.87±1.57 hours versus 3.8±1.72 hours among controls, so a minimum sample of 150 patients, divided into three equal groups (50 patients each), will achieve 80% power at 0.05 significance level. Sample size calculated using OpenEpi, Version 3, open source calculator-(SSMean).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years.
  • Nulliparous.
  • Vertex presentation.
  • Singleton pregnancy.
  • Gestational age ≥ 39 weeks according to a reliable date for the last menstrual period or a first-trimester ultrasound evaluation.
  • No contraindication for vaginal delivery.

Exclusion criteria

  • Indication for cesarean section e. g. Placenta previa, intrauterine growth retardation, non-vertex presentation and previous cesarean section.
  • Maternal medical disorders as diabetes mellitus and severe pre-eclampsia.
  • Preterm labour and preterm rupture of membranes.
  • Gestational age <39 weeks of gestation.
  • Fetal macrosomia > 4kg (estimated by u/s).

Treatment and study plan

Dexamethasone (Decadron) 8mg IM injection

Drug

one dose of IM dexamethasone sodium phosphate 8 mg (2 mL) given at the start of labour induction

Misoprostol 25 mcg

Drug

vaginal misoprostol 25 μg tablets every 6 h, up to 4 tablets, for a maximum duration of 24 h.

Both Misoprostol 25 mcg & Dexamethasone 8mg IM injection

Drug

one dose of IM dexamethasone sodium phosphate 8mg (2mL) with the first dose of vaginal misoprostol 25 μg tablets that will be given every 6 h, up to 4 tablets, for a maximum duration of 24 h.

Primary outcomes

  1. The interval between initiation of induction and beginning of the active phase of labour.

    Time frame: The interval between initiation of induction and beginning of the active phase of labour, assessed hourly up to 24 hours.

    Assessed hourly

Secondary outcomes

  1. Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation).

    Time frame: Duration of active phase of labour (starting with cervical dilatation of 4-5 cm up to full cervical dilatation), assessed hourly up to 24 hours.

    Assessed hourly

  2. Duration of second stage of labour

    Time frame: Recorded immediately with delivery of the baby

  3. Mode of delivery

    Time frame: After induction attempt (24 hours)

    Vaginal or Cesarean

  4. Fetal outcome

    Time frame: At 1 and 5 minutes after delivery

    APGAR score

  5. Fetal Outcome

    Time frame: Recorded within 24 hours after delivery

    NICU admission

Study contacts

Contact information is provided by the study sponsor or research team.

Abdelfatah M Eldesouky, MD, MRCOG

CONTACT

[email protected]

00201003370784

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 7, 2025
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.